Contact
searchSearch
HMP Global
Login

Psychedelics News

A clinician in the lab pulls a psilocybin mushroom from a bag using tweezers major depressive disorder mdd treatment
News
Single-Dose Psilocybin Rapidly Improves MDD Symptoms, RCT Finds
05/19/2026
Brionna Mendoza
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was associated with a significant reduction in depressive symptoms within 2 days of administration in patients with major depressive disorder (MDD), according to randomized control trial results.
A single dose of psilocybin was...
05/19/2026
Psych Congress Network
A patient receives psychedelic-assisted therapy
News
Presidential Executive Order Seeks to Expand Psychedelic Access for Tough-To-Treat Mental Illnesses
04/29/2026
Brionna Mendoza
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” which aims to expand psychedelic therapy access for significant mental health issues, such as suicidality, major...
President Donald J. Trump signed...
04/29/2026
Psych Congress Network
a man with depression looks out a window major depressive disorder
Research Summary
Psilocybin Produces Mixed Outcomes in Phase 2b MDD Study
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical trial found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive disorder (MDD).
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network
a woman sits on a windowsill and looks out the window
Research Summary
Inhaled Psychedelic Therapy Shows Rapid TRD Relief in Phase 2b Trial
03/27/2026
Brionna Mendoza
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD). 
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD). 
A phase 2b randomized clinical...
03/27/2026
Psych Congress Network
psilocybin-containing mushrooms in a beaker
Research Summary
Synthetic Psilocybin Meets Primary Endpoint in Phase 3 Treatment-Resistant Depression Trial
02/19/2026
Maria Mantas
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin...
02/19/2026
Psych Congress Network
woman experiencing depression
Research Summary
Nitrous Oxide May Offer Rapid-Acting Depression Relief
12/01/2025
Maria Mantas
A systematic review and meta-analysis of 7 clinical trials and 4 published protocol papers found that nitrous oxide (N2O) may offer rapid-acting benefit for the treatment of depression.
A systematic review and meta-analysis of 7 clinical trials and 4 published protocol papers found that nitrous oxide (N2O) may offer rapid-acting benefit for the treatment of depression.
A systematic review and...
12/01/2025
Psych Congress Network
Some Psychedelics Could Hold Promise for OUD Treatment
News
Some Psychedelics Could Hold Promise for OUD Treatment
01/23/2025
Evi Arthur
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
Psychedelics could be a...
01/23/2025
Psych Congress Network
fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
Brionna Mendoza
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
News
Secondary Analysis Shows Which Patients With TRD Benefit Most From Ketamine
07/24/2024
Jolynn Tumolo
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with greater treatment response than electroconvulsive therapy in patients with nonpsychotic treatment-resistant depression who had moderately severe or severe pretreatment symptoms and who initiated treatment as...
Ketamine was associated with...
07/24/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use